Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial
Raymond R. Townsend(University of Pennsylvania), Michael Böhm(Saarland University), Manesh R. Patel(Clinical Research Institute), Kazuomi Kario(Jichi Medical University), David P. Lee, Martin T. Rothman(Barts Health NHS Trust), Stuart Pocock(University of London), James W. Choi(Baylor Jack and Jane Hamilton Heart and Vascular Hospital), Sebastian Ewen(Saarland University), Felix Mahfoud(Saarland University), Vanessa DeBruin(Medtronic (United States)), Michael A. Weber(SUNY Downstate Health Sciences University), Axel Schmid(Universitätsklinikum Erlangen), Roland E. Schmieder, Debbie L. Cohen(University of Pennsylvania), George Dangas, Cara East(Baylor Jack and Jane Hamilton Heart and Vascular Hospital), Kiritkumar Patel, Martin Fahy(Medtronic (United States)), Konstantinos Tsioufis(Hippocration General Hospital), Neil Chapman, David E. Kandzari(Piedmont Atlanta Hospital), Philipp Lurz, Janice P. Lea, Jiro Aoki, Denise Jones(Medtronic (United States)), Ingrid Hopper(The Alfred Hospital), Chandan Devireddy, David Kandzari(Piedmont Atlanta Hospital), Karl Fengler(Leipzig Heart Institute), Shukri David(Piedmont Atlanta Hospital), Andrew S.P. Sharp, Justin E. Davies, Robert Wilensky, A. Walton(The Alfred Hospital), Dimitrios Tousoulis(National and Kapodistrian University of Athens), Adrian Ma(Stanford Health Care), Anthony Watkinson(Royal Devon and Exeter Hospital), Sidney A. Cohen(University of Pennsylvania), Bryan Batson
Cited by 734
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k